Drug Trial Radar · NCT02842853
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,344
Actual
Start
Jul 15, 2016
Primary completion
Feb 28, 2017
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra®, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US). Primary Objectives: * To demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs). * To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra®. Secondary Objective: * To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adult population (18 to 55 years old). * To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adolescent population (10 to 17 years old). * To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination. * To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra®. Observational Objectives: * To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra®.
Conditions
- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological
0.5 mL, Intramuscular
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate VaccineTime frame: Day 30 (post-vaccination)
- Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® VaccineTime frame: Day 30 (post-vaccination)
Locations
89 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Dothan, Alabama
Site not named
Mobile, Alabama
Site not named
Glendale, Arizona
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Harrisburg, Arkansas
Site not named
Jonesboro, Arkansas
Site not named
Anaheim, California
Site not named
Downey, California
Site not named
Los Angeles, California
Site not named
Paramount, California
Site not named
Redding, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Santa Rosa, California
Site not named
Upland, California
Site not named
West Covina, California
Site not named
Littleton, Colorado
Site not named
DeLand, Florida
Site not named
Hialeah, Florida
Site not named
Hialeah, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
South Miami, Florida
Site not named
St. Petersburg, Florida
Site not named
West Palm Beach, Florida
Site not named
Savannah, Georgia
Site not named
Meridian, Idaho
Site not named
Council Bluffs, Iowa
Site not named
Lenexa, Kansas
Site not named
Newton, Kansas
Site not named
Park City, Kansas
Site not named
Wichita, Kansas
Site not named
Wichita, Kansas
Site not named
Bardstown, Kentucky
Site not named
Metairie, Louisiana
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.